Retour

VALNEVA (EPA:VLA) Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in Europe

Directive transparence : information réglementée

23/06/2022 15:16

24/06/2022 18:00

Valneva Receives Marketing Authorization in Europe for Inactivated...

23/06/2022 16:00

Valneva announces resumption of trading of its ordinary shares on Euronext...

23/06/2022 15:16

Valneva Receives Positive CHMP Opinion for Marketing Authorization of its...

14/04/2022 12:50

Valneva Receives Conditional Marketing Authorization from UK MHRA for its...

10/02/2022 15:41

Original-Research: Valneva SE (von First Berlin Equity Research GmbH):...

04/02/2022 19:30

VALNEVA SE Declaration of shares and voting rights - January 2022

31/01/2022 22:15

Valneva Announces Initiation of Adolescent Phase 3 Trial for its...

27/01/2022 11:16

Original-Research: Valneva SE (von First Berlin Equity Research GmbH):...

23/12/2021 17:45

Valneva and Scottish Enterprise in Advanced Discussions for Major Grant to...

21/12/2021 19:05

Valneva Announces Positive Lot-to-Lot Consistency Trial Results for its...

Voir tous les communiqués de VALNEVA